10058-F4: A Next-Generation c-Myc-Max Dimerization Inhibitor for Apoptosis and Cancer Research

Introduction

The transcription factor c-Myc is a master regulator of cell growth, proliferation, and metabolism. Its aberrant activation underlies the pathology of numerous cancers, including acute myeloid leukemia (AML) and prostate cancer. Recent advances in small-molecule inhibitors have enabled researchers to dissect c-Myc-driven oncogenic pathways with unprecedented precision. Among these, 10058-F4 (SKU: A1169) stands out as a potent, cell-permeable c-Myc-Max dimerization inhibitor, directly targeting a critical protein-protein interaction essential for c-Myc's oncogenic functions. This article provides an in-depth scientific review of 10058-F4, its mechanism of action, and its emerging applications in apoptosis assay development, cancer biology, and beyond.

The Central Role of c-Myc/Max Heterodimerization in Cancer Biology

c-Myc operates as a transcription factor by forming heterodimers with its binding partner Max. This complex binds specific DNA sequences (E-box elements), activating transcriptional programs that promote cell cycle progression, metabolism, and survival. Disrupting the c-Myc/Max heterodimerization impedes c-Myc’s capacity to drive oncogenesis, making it a high-value target for research and therapeutic intervention.

Why Inhibit c-Myc/Max Interactions?

Traditional strategies to target c-Myc have been hindered by its intrinsically disordered structure and lack of enzymatic activity. Small-molecule disruption of the c-Myc/Max interface circumvents these challenges, offering a pathway-specific approach to suppress c-Myc-driven transcription without affecting unrelated cellular processes. The clinical relevance is underscored by c-Myc's role in aggressive, therapy-resistant tumors and its intersection with stem cell maintenance and DNA repair, as recently illuminated in studies on telomerase (TERT) regulation (Stern et al., 2024).

Mechanism of Action of 10058-F4: Disrupting the c-Myc/Max Axis

10058-F4 [(5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one] is a novel, cell-permeable small molecule. Its selective inhibition of c-Myc-Max heterodimerization is achieved by binding directly to the c-Myc bHLHZip domain, precluding its interaction with Max. This blocks c-Myc's binding to E-box DNA elements, effectively shutting down c-Myc-driven transcriptional programs. As a result, 10058-F4 induces a cascade of cellular events:

• Suppression of c-Myc mRNA and protein levels
• Cell cycle arrest at the G1 phase
• Activation of the mitochondrial apoptosis pathway, including modulation of Bcl-2 family proteins and cytochrome C release

This mechanistic specificity distinguishes 10058-F4 from non-selective cytotoxic agents, enabling targeted apoptosis induction in c-Myc-dependent cell populations.

Experimental Evidence: In Vitro and In Vivo Efficacy

Acute Myeloid Leukemia Research

10058-F4 demonstrates potent, dose-dependent pro-apoptotic effects in AML cell lines, including HL-60, U937, and NB-4. Notably, apoptosis induction correlates with both decreased c-Myc transcript/protein levels and mitochondrial pathway activation. For example, at 100 μM for 72 hours, robust apoptosis is observed, confirming its utility as a cell-permeable c-Myc inhibitor for apoptosis research and mechanistic studies of the c-Myc/Max heterodimer disruption pathway.

Prostate Cancer Xenograft Model

In vivo, intravenous administration of 10058-F4 in SCID mice bearing DU145 and PC-3 prostate cancer xenografts led to significant, though variable, tumor growth suppression. These findings validate 10058-F4 as a valuable tool for probing c-Myc dependency in solid tumors and for preclinical modeling of targeted c-Myc inhibition.

Chemical Properties and Handling Considerations

• Molecular Weight: 249.35 g/mol
• Solubility: ≥24.9 mg/mL in DMSO; ≥2.64 mg/mL in ethanol; insoluble in water
• Formulation: Supplied as a solid
• Storage: Store at -20°C; solutions should be prepared fresh and used promptly

These properties ensure 10058-F4’s compatibility with a broad array of in vitro and in vivo applications, from apoptosis assays to xenograft studies.

Comparative Analysis: 10058-F4 Versus Alternative Approaches

Traditional methods to inhibit c-Myc activity include RNA interference, dominant-negative mutants (such as omomyc), and CRISPR-mediated gene editing. However, these strategies often lack temporal control, exhibit off-target effects, or are challenging to deliver in vivo. In contrast, 10058-F4 offers:

• Rapid, reversible inhibition of c-Myc-Max dimerization
• Cell-permeability for efficient uptake in diverse cell types
• Suitability for both acute and chronic studies in cell culture and animal models

This makes 10058-F4 particularly attractive for high-throughput apoptosis assays and pathway dissection where specificity and flexibility are paramount.

Note: At the time of writing, no comprehensive reviews in our content library address the advanced mechanistic aspects of small-molecule c-Myc inhibitors like 10058-F4 in the context of mitochondrial apoptosis or emerging links to telomerase regulation. This article fills that gap by integrating the latest research and translational perspectives.

Advanced Applications: Beyond Standard Apoptosis Assays

Dissecting the Mitochondrial Apoptosis Pathway

Through the modulation of Bcl-2 family proteins and induction of cytochrome C release, 10058-F4 provides a powerful tool to interrogate the mitochondrial apoptosis pathway in cancer and stem cell contexts. Its use enables researchers to:

• Disentangle c-Myc-specific apoptotic signaling from general cytotoxicity
• Profile the temporal dynamics of cell death in response to transcription factor inhibition
• Validate candidate biomarkers of c-Myc pathway dependence in patient-derived samples

c-Myc and Telomerase (TERT) Regulation: New Frontiers in Oncogenic Pathways

Recent work (Stern et al., 2024) has revealed that efficient TERT (telomerase reverse transcriptase) expression in human embryonic stem cells requires the DNA repair enzyme APEX2. Given c-Myc’s established role as a direct regulator of TERT transcription, 10058-F4 emerges as an ideal probe to study the intersection of c-Myc signaling, telomerase activity, and DNA repair. This is especially relevant for:

• Understanding cancer cell immortality and resistance mechanisms
• Modeling stem cell maintenance and aging-related telomere dynamics
• Elucidating the effects of DNA damage response elements (e.g., APEX2) on c-Myc/TERT networks

Thus, 10058-F4 is not only a tool for apoptosis research but also for unraveling the intricate regulation of gene expression at the nexus of oncogenesis and stem cell biology.

Practical Considerations: Experimental Design and Limitations

To maximize the experimental utility of 10058-F4, researchers should consider:

• Optimal dosing (commonly 50–100 μM for in vitro studies)
• Time-course analysis to distinguish early versus late apoptotic events
• Appropriate solvent controls due to insolubility in water
• Prompt use of prepared solutions to maintain compound integrity

While 10058-F4 is highly selective, off-target effects at higher concentrations and variability in in vivo efficacy (as seen in prostate cancer xenograft models) warrant careful experimental controls and validation.

Conclusion and Future Outlook

10058-F4 represents a paradigm shift in targeted cancer research, enabling precise dissection of the c-Myc/Max axis and its downstream apoptotic pathways. Its integration into apoptosis assays, acute myeloid leukemia research, and prostate cancer xenograft models underscores its versatility and scientific value. Moreover, the emerging connections between c-Myc, telomerase regulation, and DNA repair machinery (as highlighted by Stern et al., 2024) position 10058-F4 at the forefront of investigations into cancer cell immortality and therapeutic resistance.

As the field advances, combining 10058-F4 with next-generation genomic and proteomic approaches promises to yield even deeper insights into oncogenic pathway vulnerabilities. For detailed product specifications and ordering information, visit the 10058-F4 product page.